Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339

No abstract is available for this paper.

• Publication year

  2010

• Venue

  JBIC Journal of Biological Inorganic Chemistry

• Publication date

  2010-03-11

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00775-010-0642-1PMID 20221888PMCID PMC3371400
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR

  2010cited by this paper
• Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells.

  2009cited by this paper
• Unusual DNA binding modes for metal anticancer complexes.

  2009cited by this paper
• A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP.

  2009cited by this paper
• Strategies to improve the efficacy of platinum compounds.

  2009cited by this paper
• Cell death and autophagy: cytokines, drugs, and nutritional factors.

  2008cited by this paper
• New cellular tools reveal complex epithelial–mesenchymal interactions in hepatocarcinogenesis

  2008cited by this paper
• Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.

  2008cited by this paper
• Intracellular Iron Transport and Storage: From Molecular Mechanisms to Health Implications

  2008cited by this paper
• Direct visualization and quantification of the anticancer agent, cis‐diamminedichloro‐platinum(II), in human lung cancer cells using in‐air microparticle‐induced X‐ray emission analysis

  2008cited by this paper
• The proteasome and its role in the degradation of oxidized proteins

  2008cited by this paper
• New trends for metal complexes with anticancer activity.

  2008cited by this paper
• Resistance against novel anticancer metal compounds: differences and similarities.

  2008cited by this paper
• Acquisition of Cisplatin-resistance in Malignant Mesothelioma Cells Abrogates Na+,K+,2Cl-;-cotransport Activity and Cisplatin-induced Early Membrane Blebbing

  2008cited by this paper
• Mechanisms underlying the anticancer activities of the angucycline landomycin E.

  2007cited by this paper
• An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.

  2007cited by this paper
• Characterisation of zinc-binding domains of peroxisomal RING finger proteins using size exclusion chromatography/inductively coupled plasma-mass spectrometry

  2007cited by this paper
• Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins

  2007cited by this paper
• Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).

  2007cited by this paper
• Ruthenium complexes can target determinants of tumour malignancy.

  2007cited by this paper
• From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

  2006cited by this paper
• DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.

  2006cited by this paper
• Studying metal integration in native and recombinant copper proteins by hyphenated ICP-DRC-MS and ESI-TOF-MS capabilities and limitations of the complementary techniques

  2006cited by this paper
• Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP.

  2006cited by this paper
• Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24).

  2006cited by this paper
• The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells.

  2005cited by this paper
• Intrinsic and Acquired Forms of Resistance against the Anticancer Ruthenium Compound KP1019 [Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A)

  2005cited by this paper
• Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells

  2005cited by this paper
• Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins

  2005cited by this paper
• Ruthenium antimetastatic agents.

  2004cited by this paper
• Targeted inactivation of p53 in human cells does not result in aneuploidy.

  2002cited by this paper
• Expression of the major vault protein LRP in human non‐small‐cell lung cancer cells: Activation by short‐term exposure to antineoplastic drugs

  2000cited by this paper
• Glutathione and the regulation of cell death.

  1999cited by this paper
• Synthesis, Characterization and Solution Chemistry of trans-Indazoliumtetrachlorobis(Indazole)Ruthenate(III), a New Anticancer Ruthenium Complex. IR, UV, NMR, HPLC Investigations and Antitumor Activity. Crystal Structures of trans-1-Methyl-Indazoliumtetrachlorobis-(1-Methylindazole)Ruthenate(III) an

  1996cited by this paper

• Recent advancements in green synthesis of anticancer metal complexes designed with nitrogen occupied organic molecules

  2026cites this paper
• Mitochondria-targeted iridium(III)-PF-06840003 conjugates: Apoptosis induction, IDO inhibition and ICD response.

  2025cites this paper
• Mechanical cues rewire lipid metabolism and support chemoresistance in epithelial ovarian cancer cell lines OVCAR3 and SKOV3

  2025cites this paper
• Metal-based immunogenic cell death inducers for cancer immunotherapy

  2025cites this paper
• Cycloruthenated thiophene-imines: novel anticancer agents

  2025cites this paper
• From metallodrug design to halochromic nanocarrier delivery: revitalizing the anticancer efficacy and biocompatibility of cyclometalated Ru(II) complex.

  2025cites this paper
• A Glance on target specific PDT active cyclometalated iridium complexes

  2024cites this paper
• Novel tris-bipyridine based Ru(II) complexes as type-I/-II photosensitizers for antitumor photodynamic therapy through ferroptosis and immunogenic cell death.

  2024cites this paper
• Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97 and ruthenium-103.

  2024cites this paper
• Navigating the landscape of the unfolded protein response in CD8+ T cells

  2024cites this paper
• Synthesis, characterization, and anticancer activity of Ru(p-cymene) complexes bearing pyrazolyl–pyridine type ligands

  2024cites this paper
• Ruthenium complexes for breast cancer therapy

  2023cites this paper
• Metal-Based Anticancer Complexes and p53: How Much Do We Know?

  2023cites this paper
• Critical Evaluation of Cell Lysis Methods for Metallodrug Studies in Cancer Cells.

  2023cites this paper
• Encapsulation of Ru(II) Polypyridine Complexes for Tumor-Targeted Anticancer Therapy

  2023cites this paper
• Significant increase of anticancer efficacy in vitro and in vivo of liposome entrapped ruthenium(II) polypyridyl complexes.

  2023cites this paper
• A Dual-Pronged Approach: A Ruthenium(III) Complex That Modulates Amyloid-β Aggregation and Disrupts Its Formed Aggregates.

  2022cites this paper
• Synthesis and Characterization of Ruthenium Complexes and Their Potential and Photosensitizers for Photodynamic Therapy

  2022cites this paper
• Metallo-Drugs in Cancer Therapy: Past, Present and Future

  2022cites this paper
• Ruthenium(III) and (II) complexes containing pyridine moiety: synthesis, crystal structure and in vitro biological evaluation

  2022cites this paper
• Recent advances and application of ruthenium complexes in tumor malignancy

  2022cites this paper
• Pharmacological assessment of Ru(II) complex with GidA protein- A novel topoisomerase II inhibitor towards cancer therapeutics

  2022cites this paper
• Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics

  2022cites this paper
• A Rising Interest in the Development of Metal Complexes in Cancer Immunotherapy.

  2022cites this paper
• Conjugates of Porphyrinoid-Based Photosensitizers with Cytotoxic Drugs: Current Progress and Future Directions toward Selective Photodynamic Therapy.

  2022cites this paper
• Synthetic Strategy Towards Heterodimetallic Half-Sandwich Complexes Based on a Symmetric Ditopic Ligand

  2021cites this paper
• Synthesis, characterisation and biological activity of the ruthenium(II) complexes of the N4-tetradentate (N4-TL), 1,6-di(2'-pyridyl)-2,5-dibenzyl-2,5-diazahexane (picenBz2).

  2021cites this paper
• Ruthenium and iron metallodrugs: new inorganic and organometallic complexes as prospective anticancer agents

  2021cites this paper
• Cyclometalated Ru(II) β-carboline complexes induce cell cycle arrest and apoptosis in human HeLa cervical cancer cells via suppressing ERK and Akt signaling

  2021cites this paper
• Imidazole/4,4′-azopyridine bridging binuclear Ru(II) complexes: design, synthesis, bimolecular interactions and cytotoxicity against HeLa cell line

  2021cites this paper
• Die Wechselwirkung mit ribosomalen Proteinen begleitet die Stressinduktion des Wirkstoffkandidaten BOLD‐100/KP1339 im endoplasmatischen Retikulum

  2021cites this paper
• Half sandwiched RutheniumII complexes: En Route towards the targeted delivery by Human Serum Albumin (HSA)

  2021cites this paper
• Detection of Ru potential metallodrug in human urine by MALDI-TOF mass spectrometry: Validation and options to enhance the sensitivity.

  2021cites this paper
• Evaluation of biomolecular interactions and cytotoxic activity of organometallic binuclear Ru(II) complexes of ferrocenyl thiosemicarbazones

  2020influential citation
• Targeted Cancer Therapies, From Small Molecules to Antibodies

  2020cites this paper
• Interaction with Ribosomal Proteins Accompanies Stress Induction of the Anticancer Metallodrug BOLD‐100/KP1339 in the Endoplasmic Reticulum

  2020cites this paper
• The Anticancer Activity of Indazole Compounds: A Mini Review.

  2020cites this paper
• Ruthenium(III) complexes with imidazole ligands that modulate the aggregation of the amyloid-β peptide via hydrophobic interactions.

  2020cites this paper
• Ru(II) Complexes Bearing O, O-Chelated Ligands Induced Apoptosis in A549 Cells through the Mitochondrial Apoptotic Pathway

  2020cites this paper
• Novel cyclometalated Ru(II) complexes containing isoquinoline ligands: Synthesis, characterization, cellular uptake and in vitro cytotoxicity.

  2020cites this paper
• Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems

  2020influential citation
• Proteomic analysis of the S. cerevisiae response to the anticancer ruthenium complex KP1019.

  2020cites this paper
• Reduced amino acid Schiff base containing ruthenium(III) complexes: Synthesis, characterization, DNA interaction, and in vitro cytotoxicity.

  2020cites this paper
• Bioreducible and traceable Ru(III) prodrug-loaded mesoporous silica nanoparticles for sequentially targeted nonsmall cell lung cancer chemotherapy

  2020cites this paper
• Ruthenium Based Anticancer Compounds and Their Importance

  2020cites this paper
• Combination of Ruthenium Complex and Doxorubicin Synergistically Inhibits Cancer Cell Growth by Down-Regulating PI3K/AKT Signaling Pathway

  2020cites this paper
• Synthesis, Modification, and Biological Evaluation of a Library of Novel Water‐Soluble Thiopyridone‐Based Organometallic Complexes and Their Unexpected (Biological) Behavior

  2020cites this paper
• Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy.

  2019cites this paper
• Screening and Preliminary Biochemical and Biological Studies of [RuCl(p-cymene)(N,N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models

  2019cites this paper
• Binuclear ruthenium(II) complexes of 4,4′-azopyridine bridging ligand as anticancer agents: synthesis, characterization, and in vitro cytotoxicity studies

  2019cites this paper
• Organometallic binuclear Ru(II) complexes: Design, synthesis, DNA/BSA binding interactions and in-vitro cytotoxicity against HeLa cell line

  2019cites this paper
• Polymer encapsulation of ruthenium complexes for biological and medicinal applications

  2019cites this paper
• NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry

  2019cites this paper
• Induction of transferrin aggregation by indazolium [tetrachlorobis(1H-indazole)ruthenate(iii)] (KP1019) and its biological function

  2019cites this paper
• Design, synthesis and in vitro bioactivity of mixed ligand Ru(II) complexes bearing the fluoroquinolone antibacterial agents

  2019cites this paper
• Chemistry and reactivity of ruthenium(II) complexes: DNA/protein binding mode and anticancer activity are related to the complex structure

  2019cites this paper
• Design of Protein-Targeted Organometallic Complexes as Anticancer Agents.

  2019cites this paper
• Inorganic Coordination Chemistry: Where We Stand in Cancer Treatment?

  2018cites this paper
• Analysis of ruthenium anticancer agents by MEEKC‐UV and MEEKC–ICP‐MS: Impact of structural motifs on lipophilicity and biological activity

  2018cites this paper
• Critical assessment of different methods for quantitative measurement of metallodrug-protein associations

  2018cites this paper
• Suppression of stress induction of the 78-kilodalton glucose regulated protein (GRP78) in cancer by IT-139, an anti-tumor ruthenium small molecule inhibitor

  2018cites this paper
• Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and an Experimental Organometallic Drug for Melanoma Treatment.

  2018cites this paper
• RuII( p-cymene) Compounds as Effective and Selective Anticancer Candidates with No Toxicity in Vivo.

  2018cites this paper
• Applications of Ruthenium Complex in Tumor Diagnosis and Therapy

  2018cites this paper
• Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNAPhe.

  2018cites this paper
• Title Ligand substitutions between ruthenium – cymene compounds can control protein versus DNA targeting and anticancer activity

  2018cites this paper
• Metallomic study on the metabolism of RAPTA-C and cisplatin in cell culture medium and its impact on cell accumulation.

  2018cites this paper
• Ruthenium Anticancer Agents—From Cisplatin Analogues to Rational Drug Design

  2017cites this paper
• Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity

  2017cites this paper
• Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates.

  2017cites this paper
• Ruthenium complex exerts antineoplastic effects that are mediated by oxidative stress without inducing toxicity in Walker‐256 tumor‐bearing rats

  2017cites this paper
• Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis.

  2017cites this paper
• Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance

  2017cites this paper
• Multi-Target Metal-Based Anticancer Agents.

  2017cites this paper
• Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.

  2017cites this paper
• Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse

  2017cites this paper
• Mixed ligand ruthenium arene complexes containing N-ferrocenyl amino acids: Biomolecular interactions and cytotoxicity against MCF7 cell line

  2017cites this paper
• Thirty Years of the Drug Candidate NAMI‐A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective

  2017cites this paper
• Organoruthenium(II) compounds with pyridyl benzoxazole/benzthiazole moiety: studies on DNA/protein binding and enzyme mimetic activities

  2017cites this paper
• Spectroscopic and cytotoxic characteristics of (p-cymene)Ru(II) complexes with bidentate coumarins and density functional theory comparison with selected Pd(II) complexes

  2017cites this paper
• Iron(III) Pincer Complexes as a Strategy for Anticancer Studies

  2017cites this paper
• Speciation of metal drugs, supplements and toxins in media and bodily fluids controls in vitro activities

  2017cites this paper
• Anticancer activity of heterodinuclear ruthenium(II)–platinum(II) complexes as photochemotherapeutic agents

  2017cites this paper
• Potencial antineoplásico do complexo de rutênio (RuC) em modelos tumorais in vitro e in vivo

  2017cites this paper
• Trends and Perspectives of Ruthenium Anticancer Compounds (Non‐PDT)

  2017cites this paper
• Interactions of ruthenium(II) compounds with sulfasalazine and N,N′-heterocyclic ligands with proteins

  2017cites this paper
• RuIII Complexes for Anticancer Therapy: The Importance of Being Nucleolipidic

  2017cites this paper
• Review: recent advances and future development of metal complexes as anticancer agents

  2017cites this paper
• Ruthenium‐Based Anticancer Compounds: Insights into Their Cellular Targeting and Mechanism of Action

  2017cites this paper
• In vitro and in vivo antitumor activity of a novel carbonyl ruthenium compound, the ct-[RuCl(CO)(dppb)(bipy)]PF-6[dppb=1,4-bis(diphenylphosphine)butane and bipy=2,2'-bipyridine].

  2016cites this paper
• Aquation Is a Crucial Activation Step for Anticancer Action of Ruthenium(II) Polypyridyl Complexes to Trigger Cancer Cell Apoptosis.

  2016cites this paper
• Epigenetic modulation by inorganic metal complexes

  2016cites this paper
• Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.

  2016cites this paper
• Synthesis, structures, and DNA and protein binding of ruthenium(II)-p-cymene complexes of substituted pyridylimidazo[1,5-a]pyridine: enhanced cytotoxicity of complexes of ligands appended with a carbazole moiety

  2016cites this paper
• Elucidation of the binding sites of two novel Ru(II) complexes on bovine serum albumin.

  2016cites this paper
• Interactions between proteins and Ru compounds of medicinal interest: A structural perspective

  2016cites this paper
• Biomedical and Pharmaceutical Applications

  2016cites this paper
• Role of metallomic strategies in developing ruthenium anticancer drugs

  2016cites this paper
• Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes.

  2016cites this paper
• Anticancer activity studies of ruthenium(II) polypyridyl complexes against human gastric carcinoma SGC-7901 cell

  2016cites this paper